Product news

Share this article:

Genzyme announced the US launch of phosphate binder Renvela (sevelamer carbonate) for dialysis patients. Renvela is a next-generation version of Renagel (sevelamer hydrochloride). It is a calcium-free, metal-free, non-absorbed phosphate binder and is available in the US as 800 mg tablets.

Onset Therapeutics, a specialty pharmaceutical company that focuses on the development and commercialization of innovative treatments for skin and skin-related disorders, has launched Anestafoam, a novel topical foam formulation containing lidocaine 4%.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.